Quantitative analysis of integrin expression in effusions using flow cytometric immunophenotyping

Diagnostic Cytopathology

Volumn 33, Issue 5, 2005, Pages 325-331

  Sigstad, Eva ^a   Dong, Hiep Phuc ^a   Nielsen, Søren ^b   Berner, Aasmund ^a   Davidson, Ben ^a   Risberg, Björn ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Adhesion molecules; Carcinoma; Flow cytometry; Mesothelium; Serous effusions

Indexed keywords

ALPHA6 INTEGRIN; BETA1 INTEGRIN; BETA3 INTEGRIN; CD14 ANTIGEN; CD15 ANTIGEN; CD45 ANTIGEN; CD51 ANTIGEN; CELL ADHESION MOLECULE; EPITHELIAL MEMBRANE ANTIGEN; FIBRONECTIN; INTEGRIN; LAMININ; VITRONECTIN;

ADENOCARCINOMA; BREAST CARCINOMA; CARCINOMA; CELL ADHESION; COLON CARCINOMA; CONFERENCE PAPER; CONTROLLED STUDY; EFFUSION; ESOPHAGUS CARCINOMA; EXTRACELLULAR MATRIX; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; KRUSKAL WALLIS TEST; MALIGNANT MESOTHELIOMA; METASTASIS; OVARY CARCINOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS;

ASCITIC FLUID; CARCINOMA; EXTRACELLULAR MATRIX; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; INTEGRINS; MALE; MESOTHELIOMA; NEOPLASM METASTASIS; PLEURAL EFFUSION, MALIGNANT; PROTEIN SUBUNITS; TUMOR MARKERS, BIOLOGICAL;

EID: 27744579762     PISSN: 87551039     EISSN: None     Source Type: Journal    
DOI: 10.1002/dc.20282     Document Type: Conference Paper

References (46)

1. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992;69:11-25.
2. Howe A, Aplin AE, Alahari SK, Juliano RL. Integrin signaling and cell growth control. Curr Opin Cell Biol 1998;10:220-231.
3. Dedhar S. Cell-substrate interactions and signaling through ILK. Curr Opin Cell Biol 2000;12:250-256.
4. Ruoslahti E. Integrins. J Clin Invest 1991;87:1-5.
5. Sanders RJ, Maniero F, Giancotti FG. The role of integrins in tumorigenesis and metastasis. Cancer Invest 1998;16:329-344.
6. Bedrossian CWM. Malignant effusions: A multimodal approach to cytologic diagnosis. New York: Igaku-Shoin; 1994.
7. Flam F, Einhorn N, Sjövall K. Symptomatology of ovarian cancer. Eur J Obstet Gynecol Reprod Biol 1988;27:53-57.
8. Kosary CL. FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-1987 SEER cases of cancers of the endometriumm, cervix, ovary, vulva, and vagina. Semin Surg Oncol 1994;10:31-46.
9. Zellos LS, Sugarbaker DJ. Diffuse malignant mesothelioma of the pleural space and its management. Oncology 2002;16:907-913.
10. Dieterich M, Goodman SN, Rojas-Corona RR, Emralino AB, Jimenez-Joseph D, Sherman ME. Multivariate analysis of prognostic features in malignant pleural effusions from breast cancer patients. Acta Cytol 1994;38:945-952.
11. Banerjee AK, Willetts I, Robertson JF, Blarney RW. Pleural effusion in breast cancer: a review of the Nottingham experience. Eur J Surg Oncol 1994;20:33-36.
12. Davidson B, Dong HP, Berner A, et al. Detection of malignant epithelial cells in effusions using flow cytometric immunophenotyping: an analysis of 92 cases. Am J Clin Pathol 2002;118:85-92.
13. Davidson B, Risberg B, Kristensen G, et al. Detection of cancer cells in effusions from patients diagnosed with gynaecological malignancies: evaluation of live epithelial markers. Virchows Arch 1999;435;43-49.
14. Davidson B, Nielsen S, Christensen J, et al. The role of Desmin and N-cadherin in effusion cytology. A comparative study using established markers of mesothelial and epithelial cells. Am J Surg Pathol 2001;25:1405-1412.
15. Chen LM, Lazcano O, Katzmann JA, Kimlinger TK, Li CY. The role of conventional cytology, immunocytochemistry, and flow cytometric DNA ploidy in evaluation of body cavity fluids: a prospective study of 52 patients. Am J Clin Pathol 1998;109:712-721.
16. Rijken A, Dekker A, Taylor S, Hoffman P, Blank M, Krause JR. Diagnostic value of DNA analysis in effusions by flow cytometry and image analysts. A prospective study on 102 patients as compared with cytologic examination. Am J Clin Pathol 1991;95:6-12.
17. Joseph MG, Banerjee D, Harris P, Gibson S, McFadden RG. Multiparameter flow cytometric DNA analysis of effusions: a prospective study of 36 cases compared with routine cytology and immunohistochemistry. Mod Pathol 1995;8:686-693.
18. Unger KM, Raber M, Bedrossian CW, Stein DA, Barlogie B. Analysis of pleural effusions using automated flow cytometry. Cancer 1983;52:873-877.
19. Evans DA, Thornthwaite JT, Ng AB, Sugarbaker EV. DNA flow cytometry of pleural effusions. Comparison with pathology for the diagnosis of malignancy. Anal Quant Cytol 1983;5:19-27.
20. Ceyhan BB, Demiralp E, Celikel T. Analysis of pleural effusions using flow cytometry. Respiration 1996;63:17-24.
21. Sikora J, Dworacki G, Zeromski J. DNA ploidy, S-phase, and Ki-67 antigen expression in the evaluation of cell content of pleural effusions. Lung 1996;174:303-313.
22. Sikora J, Dworacki G, Trybus M, Batura-Gabryel H, Zeromski J, Correlation between DNA content, expression of Ki-67 antigen of tumor cells and immunophenotype of lymphocytes from malignant pleural effusions. Tumour Biol 1998;19:196-204.
23. Risberg B, Davidson B, Dong HP, Nesland JM, Berner A. Flow cytometric immunophenotyping of serous effusions and peritoneal washings- Comparison with immunocytometry and morphological findings. J Clin Pathol 2000;53:513-517.
24. Risberg B, Davidson B, Nielsen S, et al. Detection of monocyte/macrophage cell populations in effusions: a comparative study using flow cytometric immunophenotyping and immunocytochemistry. Diagn Cytopathol 2001;25:214-219.
25. Ordonez NG. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol 2003;27:1031-1051.
26. Diaz-Arias AA, Loy TS, Bickel JT, Chapman RK. Utility of ER-EP4 in the diagnosis of adenocarcinoma in effusions: an immunocytochemical study of 232 cases. Diagn Cytopathol 1993;9:516-521.
27. Flynn MK, Johnston W, Bigner S. Carcinoma of ovarian and other origins in effusions. Immunocytochemical study with a panel of monoclonal antibodies. Acta Cytol 1993;37:439-447.
28. Robinson RJ, Royston D. Comparison of monoclonal antibodies AUA1 and BER EP4 with anti-CEA for detecting carcinoma cells in serous effusions and distinguishing them from mesothelial cells. Cytopathology 1993;4:267-271.
29. Roberts F, Harper CM, Downie I, Burnett RA. Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies. Am J Clin Pathol 2001;116:253-262.
30. Moser TL, Pizzo SV, Bafetti LM, Fishman DA, Stack MS. Evidence for preferential adhesion of ovarian epithelial carcinoma cells to type I collagen mediated by the α2β1 integrin. Int J Cancer 1996;67:695-701.
31. Cruet S, Salamanca C, Mitchell GW, Auersperg N. α(v)β3 and vitronectin expression by normal ovarian surface epithelial cells: role in cell adhesion and cell proliferation. Gynecol Oncol 1999;75:254-260.
32. Carreiras F, Rigot V, Cruet S, Andre F, Gauduchon P, Marvaldi J. Migration properties of the human ovarian adenocarcinoma cell line IGROV1: importance of α(v)β3 integrins and vitronectin. Int J Cancer 1999;80:285-294.
33. Cannistra SA, Ottensmeier C, Niloff J, Orta B, DiCarlo J. Expression and function of βl and α(v)β3 integrins in ovarian cancer. Gynecol Oncol 1995;58:216-225.
34. Strobel T, Cunnistra SA. Beta1-integrins partly mediate binding of ovarian cancer cells to peritoneal mesothelium in vitro. Gynecol Oncol 1999;73:362-367.
35. Lessan K, Aguiar DJ, Oegema T, Siebenson L, Skubitz AP. CD44 and βl integrin mediate ovarian carcinoma cell adhesion to peritoneal mesothelial cells. Am J Pathol 1999;154:1525-1537.
36. Kishikawa T, Sakamoto M, Ino Y, Kubushiro K, Nozawa S, Hirohashi S. Two distinct patterns of peritoneal involvement shown by in vivo ovarian cancer dissemination models. Invasion Metastasis 1995;15:11-21.
37. Carreiras F, Lehmann M, Sichel F, Marvaldi J, Gauduchon P, Le Talaer JY. Implication of the α(v)β3 integrin in the adhesion of the ovarian-adenocarcinoma cell line IGROV1. Int J Cancer 1995;63:530-536.
38. Liapis H, Hutton K. Detection of integrins in formalin-fixed, paraffin-embedded tissues. J Histochem Cytochem 1997;45:737-741.
39. Skubitz AP, Bast RC Jr, Wayner EA, Letourneau PC, Wilke MS. Expression of α6 and β4 integrins in serous ovarian carcinoma correlates with expression of the basement membrane protein laminin. Am J Pathol 1996;148:1445-1461.
40. Davidson B, Goldberg I, Reich R, et al. αV- and β1-integrin subunits are commonly expressed in malignant effusions from ovarian carcinoma patients. Gynecol Oncol 2003;90:248-257.
41. Koukoulis GK, Shen J, Monson R, Warren RH. Virtanen 1, Gould VE. Pleural mestheliomas have an integrin profile distinct from vis-ceral carcinomas. Hum Pathol 1997;28:84-90.
42. Earth TF, Bruderlein S, Rinaldi N, Mechtersheimer G, Moller P. Pleural mesothelioma mimics the integrin profile of activated, sessile rather than detached mesothelial cells. Int J Cancer 1997;72:77-86.
43. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer 2002;2:91-100.
44. Givant-Horwitz V, Davidson B, van de Putte G, et al. Dissociated mRNA expression of the 67kDa laminin receptor and the α6 integrin subunit in serous ovarian carcinoma. Clin Exp Metastasis 2003;20:599-609.
45. Davidson B, Konstantinovsky S, Nielsen S, et al. Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients: a novel model for tumor progression. Clin Cancer Res 2004;10:7335-7346.
46. Reich R, Vintman L, Nielsen S, et al. Differential expression of the 67 kDa laminin receptor in malignant mesothelioma and carcinomas that spread to serosal cavities. Diagn Cytopathol, In press.